GFM
ARQT icon

GF Fund Management’s Arcutis Biotherapeutics ARQT Stock Holding History

GF Fund Management’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$68.9K Sell
2,626
-125
-5% -$2.91K ﹤0.01% 363
2026
Q1 		$64.8K Buy
2,751
+345
+14% +$8.8K ﹤0.01% 374
2025
Q4 		$69.9K Sell
2,406
-174
-7% -$4.45K ﹤0.01% 375
2025
Q3 		$48.6K Sell
2,580
-416
-14% -$6.56K ﹤0.01% 398
2025
Q2 		$42K Hold
2,996
– – ﹤0.01% 434
2025
Q1 		$46.9K Buy
2,996
+538
+22% +$7.58K ﹤0.01% 428
2024
Q4 		$34.2K Buy
+2,458
New +$26.9K ﹤0.01% 425

Other funds holding ARQT

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

GF Fund Management's ARQT Position: Q2 2026 in Review

GF Fund Management reduced its Arcutis Biotherapeutics (ARQT) stake by 4.5% in Q2 2026, selling an estimated $2.91K and leaving 2,626 shares worth $68.9K. The position accounts for ﹤0.01% of the portfolio, ranked #363.

GF Fund Management first reported a position in ARQT in Q4 2024 and has held it in 7 quarters since. The position peaked at $69.9K in Q4 2025. 273 funds tracked by Wall St. Rank hold ARQT as of Q2 2026.

  • GF Fund Management held 2,626 shares of Arcutis Biotherapeutics worth $68.9K as of Q2 2026.
  • GF Fund Management sold 125 Arcutis Biotherapeutics shares in Q2 2026, an estimated $2.91K.
  • Arcutis Biotherapeutics made up ﹤0.01% of GF Fund Management's portfolio in Q2 2026, its #363 holding.
  • GF Fund Management first reported a position in Arcutis Biotherapeutics in Q4 2024 and has held it in 7 quarters since.
  • GF Fund Management's Arcutis Biotherapeutics position peaked at $69.9K in Q4 2025.
  • 273 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2026.

Based on GF Fund Management's 13F filing for Q2 2026, filed 7 Aug 2026.